Kezar Life Sciences (NASDAQ:KZR) Issues Quarterly Earnings Results, Beats Estimates By $0.28 EPS

Kezar Life Sciences (NASDAQ:KZR) released its earnings results on Wednesday. The company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.28, Zacks reports.

Kezar Life Sciences Stock Up 0.5%

Kezar Life Sciences stock traded up $0.03 during trading on Friday, reaching $6.18. 3,884 shares of the company’s stock were exchanged, compared to its average volume of 77,717. Kezar Life Sciences has a 52-week low of $3.53 and a 52-week high of $7.65. The firm has a market cap of $45.24 million, a price-to-earnings ratio of -0.73 and a beta of 0.70. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.29 and a current ratio of 7.29. The company’s 50-day moving average is $4.84 and its two-hundred day moving average is $4.45.

Analysts Set New Price Targets

A number of analysts recently issued reports on KZR shares. Wall Street Zen upgraded shares of Kezar Life Sciences to a “sell” rating in a research report on Saturday, September 13th. TD Cowen cut Kezar Life Sciences from a “strong-buy” rating to a “strong sell” rating in a report on Friday, October 17th. Jefferies Financial Group lowered Kezar Life Sciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $18.00 to $7.00 in a research note on Friday, October 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Kezar Life Sciences in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company set a $5.00 price objective on shares of Kezar Life Sciences and gave the company an “equal weight” rating in a research note on Friday, October 17th. Four research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $6.00.

Hedge Funds Weigh In On Kezar Life Sciences

A hedge fund recently bought a new stake in Kezar Life Sciences stock. Landscape Capital Management L.L.C. acquired a new stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 13,042 shares of the company’s stock, valued at approximately $51,000. Landscape Capital Management L.L.C. owned approximately 0.18% of Kezar Life Sciences as of its most recent SEC filing. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.